Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD133+ bone marrow-derived cells
- Development stage
- Unknown
- Lead developer
- Medical University of Silesia
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
Autologous CD133+ bone marrow-derived cells is an investigational cell therapy consisting of CD133+ (Prominin-1) hematopoietic and endothelial progenitor cells harvested from a patient's own bone marrow. These cells are selected for their potential to differentiate into cardiac and endothelial lineages, aiming to promote neovascularization and myocardial regeneration in ischemic tissues. The therapy is typically administered via direct transendocardial (intramyocardial) injection, often guided by electromechanical mapping (e.g., NOGA). It was primarily evaluated in the REGENT-VSEL Phase 2 trial by the Medical University of Silesia for patients with pharmacologically resistant stable angina pectoris and inducible myocardial ischemia who were not candidates for revascularization. Although the therapy demonstrated safety, clinical results showed no significant improvement in myocardial perfusion or quality of life compared to placebo.
- Other names
- autologous bone marrow-derived CD133+ cellsCD133+ bone marrow stem cells
Beyond the preview
Go deeper on autologous CD133+ bone marrow-derived cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD133+ bone marrow-derived cells.